Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $2,300 | 1 | 44.5% |
| Food and Beverage | $1,373 | 45 | 26.5% |
| Travel and Lodging | $976.73 | 4 | 18.9% |
| Unspecified | $521.48 | 1 | 10.1% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $2,300 | 1 | $0 (2021) |
| Halozyme Inc | $1,166 | 8 | $0 (2017) |
| Amgen Inc. | $521.48 | 1 | $0 (2018) |
| Bayer Healthcare Pharmaceuticals Inc. | $165.38 | 2 | $0 (2023) |
| Covidien LP | $146.02 | 1 | $0 (2018) |
| Janssen Biotech, Inc. | $130.61 | 7 | $0 (2022) |
| Medtronic USA, Inc. | $122.16 | 1 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $118.74 | 8 | $0 (2022) |
| TAIHO ONCOLOGY, INC. | $102.11 | 5 | $0 (2024) |
| GENZYME CORPORATION | $85.23 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $216.71 | 11 | TAIHO ONCOLOGY, INC. ($80.47) |
| 2023 | $172.15 | 5 | Bayer Healthcare Pharmaceuticals Inc. ($89.54) |
| 2022 | $206.70 | 12 | Janssen Biotech, Inc. ($77.97) |
| 2021 | $2,495 | 9 | Lilly USA, LLC ($2,300) |
| 2018 | $776.60 | 4 | Amgen Inc. ($521.48) |
| 2017 | $1,304 | 10 | Halozyme Inc ($1,166) |
All Payment Transactions
51 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Astellas Pharma US Inc | Vyloy (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: Oncology | ||||||
| 11/21/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: ONCOLOGY | ||||||
| 10/01/2024 | PFIZER INC. | INLYTA (Drug), PADCEV | Food and Beverage | In-kind items and services | $23.47 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $22.97 | General |
| Category: Oncology | ||||||
| 09/13/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: ONCOLOGY | ||||||
| 07/25/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: ONCOLOGY | ||||||
| 06/06/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $14.23 | General |
| Category: Oncology | ||||||
| 05/09/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $21.63 | General |
| Category: Oncology | ||||||
| 04/19/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: ONCOLOGY | ||||||
| 03/12/2024 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: Oncology | ||||||
| 10/24/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $20.83 | General |
| Category: ONCOLOGY | ||||||
| 09/11/2023 | CTI BioPharma Corp. | Vonjo (Drug) | Food and Beverage | In-kind items and services | $22.85 | General |
| Category: Hematology | ||||||
| 08/30/2023 | TAIHO ONCOLOGY, INC. | LONSURF (Drug), INQOVI | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: Oncology | ||||||
| 07/27/2023 | TerSera Therapeutics LLC | Zoladex (Drug) | Food and Beverage | In-kind items and services | $17.29 | General |
| Category: Oncology | ||||||
| 06/26/2023 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi, Nexavar | Food and Beverage | In-kind items and services | $89.54 | General |
| Category: Oncology | ||||||
| 09/08/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: ONCOLOGY | ||||||
| 08/23/2022 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Oncology | ||||||
| 08/18/2022 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $31.29 | General |
| 08/12/2022 | PFIZER INC. | BOSULIF (Drug), PAXLOVID | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 08/10/2022 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $13.46 | General |
| Category: Oncology | ||||||
| 07/20/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $12.66 | General |
| Category: ONCOLOGY | ||||||
| 06/27/2022 | Novartis Pharmaceuticals Corporation | MEKINIST (Drug) | Food and Beverage | In-kind items and services | $12.07 | General |
| Category: ONCOLOGY | ||||||
| 05/20/2022 | Novartis Pharmaceuticals Corporation | KISQALI (Drug), FEMARA | Food and Beverage | In-kind items and services | $12.56 | General |
| Category: ONCOLOGY | ||||||
| 05/18/2022 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $28.51 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A prospective, community-based observational study of chemotherapy patterns, febrile neutropenia prophylaxis, and patient satisfaction and burden associated with colony-stimulating factor injections among patients with early-stage breast cancer | Amgen Inc. | $521.48 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 24 | 655 | 29,761 | $1.5M | $163,690 |
| 2022 | 30 | 929 | 50,034 | $2.2M | $261,471 |
| 2021 | 32 | 1,092 | 78,937 | $3.7M | $505,034 |
| 2020 | 34 | 1,188 | 82,329 | $5.9M | $891,605 |
All Medicare Procedures & Services
120 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 12 | 420 | $808,703 | $41,866 | 5.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 150 | 371 | $111,916 | $36,672 | 32.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 32 | 183 | $135,969 | $19,625 | 14.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 63 | 114 | $45,928 | $15,740 | 34.3% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 18 | 68 | $54,536 | $9,706 | 17.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 49 | 49 | $30,709 | $8,242 | 26.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 21 | 113 | $38,307 | $5,980 | 15.6% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 17 | 1,720 | $37,278 | $4,968 | 13.3% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 31 | 336 | $45,024 | $4,263 | 9.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 37 | 53 | $10,500 | $3,646 | 34.7% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 16 | 94 | $15,886 | $2,183 | 13.7% |
| J9190 | Injection, fluorouracil, 500 mg | Office | 2023 | 19 | 1,092 | $17,280 | $2,086 | 12.1% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 27 | 40 | $15,680 | $2,033 | 13.0% |
| J9263 | Injection, oxaliplatin, 0.5 mg | Office | 2023 | 13 | 22,085 | $71,964 | $1,299 | 1.8% |
| 96368 | Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | Office | 2023 | 17 | 76 | $7,448 | $1,233 | 16.6% |
| 96366 | Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | Office | 2023 | 22 | 63 | $8,127 | $1,055 | 13.0% |
| 96360 | Infusion into a vein for hydration, 31-60 minutes | Office | 2023 | 12 | 36 | $11,772 | $901.68 | 7.7% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 16 | 940 | $13,630 | $799.85 | 5.9% |
| 96377 | Application of on-body injector for under skin injection | Office | 2023 | 12 | 35 | $4,060 | $529.55 | 13.0% |
| 96523 | Irrigation of implanted venous access drug delivery device | Office | 2023 | 12 | 19 | $2,451 | $353.94 | 14.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 11 | 24 | $2,784 | $278.40 | 10.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 21 | 1,210 | $858.70 | $118.90 | 13.8% |
| J7030 | Infusion, normal saline solution , 1000 cc | Office | 2023 | 11 | 36 | $675.00 | $69.21 | 10.3% |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | Office | 2023 | 16 | 584 | $753.50 | $42.82 | 5.7% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2022 | 13 | 600 | $1.2M | $78,598 | 6.8% |
About Dr. Arun Nagarajan, MD
Dr. Arun Nagarajan, MD is a Hematology & Oncology healthcare provider based in Weston, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801850268.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Arun Nagarajan, MD has received a total of $5,171 in payments from pharmaceutical and medical device companies, with $216.71 received in 2024. These payments were reported across 51 transactions from 21 companies. The most common payment nature is "Consulting Fee" ($2,300).
As a Medicare-enrolled provider, Nagarajan has provided services to 3,864 Medicare beneficiaries, totaling 241,061 services with total Medicare billing of $1.8M. Data is available for 4 years (2020–2023), covering 120 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Weston, FL
- Active Since 04/13/2006
- Last Updated 04/21/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1801850268
Products in Payments
- Neulasta (Biological) $521.48
- Stivarga (Drug) $165.38
- iDrive Ultra (Device) $146.02
- ACTIVA (Device) $122.16
- DARZALEX (Biological) $116.68
- LONSURF (Drug) $102.11
- AUBAGIO (Drug) $85.23
- JEMPERLI (Biological) $73.36
- KISQALI (Drug) $51.74
- LUTATHERA (Drug) $41.70
- IMBRUVICA (Drug) $34.76
- MEKINIST (Drug) $25.30
- Lenvima (Drug) $23.87
- INLYTA (Drug) $23.47
- Vonjo (Drug) $22.85
- Enhertu (Drug) $21.04
- Vyloy (Drug) $18.37
- BOSULIF (Drug) $18.26
- Zoladex (Drug) $17.29
- Dysport 300 U-1 (Drug) $16.10
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Weston
Dr. Chakra Chaulagain, Md, MD
Hematology & Oncology — Payments: $172,661
Adedayo Onitilo, Md, MD
Hematology & Oncology — Payments: $120,319
Chieh-Lin Fu, M.d, M.D
Hematology & Oncology — Payments: $16,690
Evan Alley, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $10,998
Tiffany George, Md, MD
Hematology & Oncology — Payments: $3,921
Dr. Diana Saravia, M.d, M.D
Hematology & Oncology — Payments: $3,022